Education
About Us
Working with TipRanks
Follow Us
Alzinova AB (SE:ALZ)
:ALZ
ALZ Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.10 - kr4.62
Previous CloseN/A
Volume98.89K
Average Volume (3M)801.49K
Market Cap
€122.06M
Enterprise Valuekr214.77M
Total Cash (Recent Filing)€3.59M
Total Debt (Recent Filing)€800.00K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Aug 21, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding104,323,586
10 Day Avg. Volume865,204
30 Day Avg. Volume801,488
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.45Price Target Upside12.64% Upside
Rating ConsensusHold
Number of Analyst Covering0
ALZ FAQ
What was Alzinova AB’s price range in the past 12 months?
Alzinova AB lowest stock price was kr1.10 and its highest was kr4.62 in the past 12 months.
What is Alzinova AB’s market cap?
Alzinova AB’s market cap is €122.06M.
When is Alzinova AB’s upcoming earnings report date?
Alzinova AB’s upcoming earnings report date is Aug 21, 2025 which is 2 days ago.
How were Alzinova AB’s earnings last quarter?
Currently, no data Available
Is Alzinova AB overvalued?
According to Wall Street analysts Alzinova AB’s price is currently Undervalued.
Does Alzinova AB pay dividends?
Alzinova AB does not currently pay dividends.
What is Alzinova AB’s EPS estimate?
Alzinova AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzinova AB have?
Alzinova AB has 104,323,586 shares outstanding.
What happened to Alzinova AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alzinova AB?
Currently, no hedge funds are holding shares in SE:ALZ
Company Description
Alzinova AB
Alzinova AB (ALZ) is a Swedish biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease. The company operates primarily in the biotechnology sector, leveraging its proprietary AβCC peptide technology to target the toxic amyloid-beta oligomers implicated in the progression of Alzheimer's. Alzinova's lead product candidate, ALZ-101, is a therapeutic vaccine designed to induce a specific immune response against these harmful oligomers.
Technical Analysis
Biosergen AB
―
Biovica International AB Class B
―
Modus Therapeutics Holding AB
―
NextCell Pharma AB
―
Nanologica AB
―